Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gambro Sale Of U.S. Dialysis Services Leaves $2 Bil. For Possible Acquisitions

This article was originally published in The Gray Sheet

Executive Summary

Gambro's plan to refocus on its core renal and blood bank product offerings by divesting its U.S. dialysis services business provides about $2 bil. for potential acquisitions in related fields

You may also be interested in...



DCA/Medicore Merger Provides Up To $10 Mil. For Dialysis Service Expansion

Dialysis Corporation of America will gain access to capital for dialysis services expansion by acquiring parent company Medicore in a stock-swap valued at $152 mil

DCA/Medicore Merger Provides Up To $10 Mil. For Dialysis Service Expansion

Dialysis Corporation of America will gain access to capital for dialysis services expansion by acquiring parent company Medicore in a stock-swap valued at $152 mil

DaVita investigated by Justice

Dialysis services firm will provide documents relating to medical director compensation, joint venture agreements with physicians and drug services to DoJ under a March 4 subpoena. The U.S. Attorney for the Eastern District of Missouri's investigation "significantly overlaps" with a similar action begun in February 2001 by the U.S. attorney in Philadelphia, the firm notes. DaVita acquisition target Gambro settled similar issues with the St. Louis attorney's office in December 2004 (1"The Gray Sheet" Dec. 13, 2004, p. 12)...

Related Content

UsernamePublicRestriction

Register

MT021303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel